Patent office frees embryonic stem cell technology

The U.S. patent office has decided to reject three existing patents on embryonic stem cell lines held by the Wisconsin Alumni Research Foundation. The patents were challenged by the Foundation for Taxpayer and Consumer Rights, which said that the work done by Wisconsin researcher James Thomson in isolating the stem cell lines was made obvious by previous scientific research. In order to win a patent, research has to be original and "non-obvious." The decision was heralded as a win for scientists in the field--who would gain free access to the technology--and a loss for Geron, which has an exclusive licensing deal on some of the stem cell technology at stake. The decision is being appealed and a final ruling will come later.

- read the report from the Milwaukee Business Journal

ALSO: Scientists in the U.K. have used stem cells harvested from bone marrow to create heart valve tissue. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.